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Abstract: Aptamers, and the selection process known as Systematic Evolution of Ligands 
by Exponential Enrichment (SELEX) used to generate them, were first described more 
than twenty years ago. Since then, there have been numerous modifications to the selection 
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procedures. This review discusses the use of modified bases as a means of enhancing 
serum stability and producing effective therapeutic tools, as well as functionalising these 
nucleic acids to be used as potential diagnostic agents. 
Keywords: aptamer; SELEX; cancer; diagnostics; locked nucleic acid; unlocked nucleic acid 
 
1. Introduction 
Aptamers are simple short strands of DNA or RNA that have been generated in the laboratory using 
in vitro selection processes. In 1990 three groups concurrently described the process of the selection of 
nucleic acids. Ellington and colleagues generated RNA molecules capable of binding organic dyes, 
while Robertson and Joyce described the generation of RNA enzymes that could specifically cleave 
DNA, and Tuerk and Gold generated RNA ligands to a bacteriophage T4 DNA polymerase [1–3]. This 
ingenious process stimulated the imagination of a group of researchers who began to explore the 
applications of this new class of nucleic acids, with exquisite three-dimensional structures, in biology 
and medicine. However, using nucleic acids as therapeutic molecules was not a new idea in 1990. 
Antisense oligonucleotides (ASOs) were first described as a means of gene silencing in 1977 [4,5], 
though these ASOs have yet to realise their therapeutic potential. Whereas ASOs bind in a  
Watson-Crick base pairing manner, aptamers interact with their targets through the complex three 
dimensional shapes that these nucleic acids fold into and thus bind via an “induced fit” mechanism. 
For this reason, aptamers are also commonly referred to as chemical antibodies. 
The process of aptamer generation is very different from that involved in ASOs and RNAi, where 
knowledge of the gene sequence is required. Aptamer selection requires no prior knowledge of the 
target sequence or even, in some cases, what the specific target is. Aptamers have been generated 
against proteins, cells and even whole organisms [6–10]. There have also been recent reports describing 
the in vivo selection of aptamers using an animal model of intrahepatic colorectal cancer [11], and of 
aptamers capable of penetrating into the brain [12]. This selection process has been termed the 
Systematic Evolution of Ligands by EXponential Enrichment (SELEX) and involves iterative rounds 
of incubation of a randomised library with a “target” (Figure 1). While this process can be time-consuming 
and tedious, it does produce aptamers with a high affinity and selectivity to the target. This process can 
generate aptamers of either RNA or DNA, with the final application generally guiding the researcher 
as to the species to use. RNA aptamers are generally considered to form much more complex three 
dimensional shapes compared to DNA aptamers. However, unmodified RNA has a half-life of seconds 
in human serum, a limiting factor in generating aptamers for therapeutic applications. Both DNA and 
RNA species are inherently susceptible to nucleases present in human serum, though DNA aptamers 
generally have a half-life of approximately 60 min [13].  
A key factor in developing oligonucleotides for therapeutic applications has been the inclusion of 
structurally modified nucleotides into the sequence. These modified nucleotides are nuclease resistance 
and thus resist exo- and endo-nuclease degradation. This has generally been performed following 
selection processes and can affect the binding properties of aptamer. It is not surprising considering 
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aptamers possess a binding region that interacts with the target via hydrogen bonding and  
van der Waals interactions [14]. Through these interactions, the aptamer binds tightly through 
conformation-based interactions. Any structural change that occurs within the binding region of the 
aptamer will therefore affect the tightness of the binding, thus reducing the binding affinity or affecting 
the specificity of the interaction [15]. The post-SELEX modification was therefore very much a trial 
and error process prior to the development of computer simulation programs, such as RNAFold and 
CENTROIDFOLD [16,17], which can predict the two-dimensional structure of the aptamer and allow 
researchers to use rational design to insert modified bases into regions of the aptamer that were 
unlikely to interact with the target, although the binding of the modified aptamer still needs to be 
confirmed by experiments. A number of modified bases can be inserted into the aptamer structure in 
this way, thus providing a way to stabilise the aptamer for in vivo therapeutic applications. 
Figure 1. Schematic of SELEX for DNA (black arrows) or RNA (grey arrows) selection. 
An initial pool of randomised DNA is amplified by PCR. This pool can be transcribed into 
RNA prior to incubation with the target of choice. Non-binding species are removed and 
the binding species are reverse transcribed (RNA aptamers) prior to PCR amplification. 
This is repeated 8–12 times to produce an enriched pool of binding species that are highly 
specific for the target. Modified from [18].  
 
2. Post-SELEX Structure Modification 
Nuclease degradation is a major issue for therapeutic nucleic acids. Studies with ASOs provided a 
useful strategy to augment the nucleic acid strand in order to prevent degradation. One common 
method has been to cap the 3'- and/or 5'- ends of the nucleic acid strand [19], which prevents attacks 
by exonucleases. Endonucleases, however, appear to have a preference for pyrimidines, with cleavage 
occurring more frequently in the case of two or more adjacent pyrimidines [20,21]. One of the first 
types of modification introduced to enhance the stability of ASOs was the use of phosphorothioate 
nucleotides as an alternative backbone. In fact, modifying the phosphate linkage has been used fairly 
effectively to improve enzymatic stability. In the case of the phosphorothioate base, one of the  
non-bridging phosphate oxygens in the phosphodiester linkage is substituted for sulphur [22]. This has 
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proven to be very effective in protecting ASOs against exonucleases when placed in the 5'- or  
3'- end of the oligonucleotide, with it appearing to be most effective when placed at the 3'-side of the 
internal pyrimidine [20]. However, it has been suggested that these are “stickier” towards proteins than 
the normal phosphodiester backbone [23], which may present a problem with aptamers and  
non-specific binding. 
The 2'-hydroxyl group plays a key role in aptamer folding/structure with the 2'-OH influencing the 
sugar conformation, though reports are conflicting as to whether this particular group plays a role in 
binding to the protein through specific hydrogen bonding interactions [24–26]. Modifications of the  
2'-position of the ribose sugar have been shown to aid in stronger base-pairing with the target, which 
can lead to increased binding specificity and RNase/nuclease resistance [19] by removing the  
2'-hydroxyl group from the sugar which is the naturally occurring cleavage site prone to nucleophilic 
attack [10]. These modifications include the incorporation of amino (NH2), fluoro (F), alkyl and thio 
groups to the 2'-position (Figure 2A).  
Figure 2. Representative structures of modified bases. (A): RNA bases can be modified at 
the 2'-OH (R) group with the substitution of fluoro, methoxy, thio or amino groups; The 
structure of locked nucleic acids is locked in place through a methylene bridge; The 
structure of unlocked nucleic acids is flexible due to the loss of the C2'-C3' bond; (B): The 
sugar ring forms an “S” or “N” type conformation, depending on the functional group (R). 
Modified from [27,28]. 
 
A study demonstrated that these types of modification increased serum stability from less than  
one second for a completely unmodified RNA aptamer, to more than 81 h [10]. Interestingly, 
modification of only one of the pyrimidines (cytosine or uridine) did not increase the half-life 
significantly (≤1 min) [10]. However, the modification of all pyrimidines with 2'-fluoro-pyrimidines 
resulted in a significant increase (81 h). When mixed bases were introduced into the structure of the 
aptamer (2'-F-C & 2'-NH2-U or 2'-F-U & 2'-NH2-C), the half-life increased to 36 h. The incorporation 
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of 2'-aminopyrimidines into all C and U positions, however, increased the half-life to approximately 
367 h. While the serum stability was significantly increased, the aptamer lost all binding capacity 
following the incorporation of 2'-NH2-pyrimidines [10] (Table 1). This may be because the 2'-amino 
groups favour a C2'-endo pucker, similar to the DNA β-helix, while 2'-fluoropyrimidines shift the 
equilibrium towards the RNA-like C3'endo form due to a higher electronegativity [10] (Figure 2B). A 
comparison of 2'-fluoro and 2'-amino selected aptamers targeting the keratinocyte growth factor 
showed that the 2'-fluoro aptamers possessed superior binding affinity to the 2'-amino modified 
aptamer [29]. Indeed, the 2'-amino-pyrimidines appear to have fallen out of favour for the 
development of therapeutic aptamers [30].  
Table 1. In vitro stability of modified aptamers. 
Modification Aptamer Half-Life Reference 
Unmodified RNA Trypanosome <1 s [10] 
2'-FP TTA1 42 h [31] out of order 
2'OMe TTA1 49 h [31]out of order 
LNA TTA1 53–72 h [31] 
2'FP & 2'NH2 Trypanosome 36 h [10] 
2'FP Trypanosome 81 h [10] 
2'NH2 Trypanosome 367 h [10] 
LNA sgc8c (c8L3) 3 h [32]out of order 
2'FP RET Receptor Tyrosine Kinase 6 h [33]out of order 
Notes: Abbreviations: 2'FP: 2'-Fluoropyrimidines; 2'OMe: 2'O-methyl: LNA: Locked nucleic acid;  
2'NH2: 2'-aminopyrimidine. 
The alkyl derivatives are possibly the most studied 2'-modification, with the 2'-O-methyl 
modification used quite extensively to modify aptamers. There are two main reasons for the 
incorporation of this modification into the aptamers: firstly, the 2'-O-methyl nucleotides are far 
cheaper to synthesise than the 2'-fluoro or 2'-amino-pyrimidines; and secondly, the 2'-O-methyl bases 
are naturally occurring nuclease resistant nucleotides [30]. As with the 2'-fluoro modification, the  
2'-OMe modifications adopt a C3'-endo conformation [34]. The first aptamer (Macugen
®
, pegaptanib 
sodium, Valenat Pharmaceuticals) approved by the US Food and Drug Administration (FDA) in 2004 
targets vascular endothelial growth factor for the treatment of age-related macular degeneration. This 
aptamer was modified with 2'-fluoro-pyrimidines and 2'-O-methyl-purines. Together with a 3'-cap and 
a polyethylene glycol molecule, the half-life of Macugen
®
 was extended to 131 h [35,36]. 
Locked nucleic acids (LNAs) were originally developed by Wengel and Imanishi in 1998 [37,38]. 
In this case the 2'-oxygen has been linked to the 4'-carbon of the ribose by a methylene bridge, thus 
completely locking the sugar in to a 3'-endo conformation [39] (Figure 2). The introduction of LNAs 
into the nucleic acid sequence has been shown to increase the binding affinity, thermodynamic 
stability and prevent serum degradation of oligonucleotides (Table 2). There are several forms of 
LNAs that have been developed—the β-D-ribo isomer, the α-L-xylo-LNA isomer, the β-D-xylo LNA 
isomer and the α-D-ribo isomer—all with similar thermostability profiles [40]. Based on the furanose 
conformation of LNAs, it would appear to be possible to directly substitute 2'fluoro-pyrimidines with 
LNAs during post-SELEX modification processes. The 2'-OMe and 2'-F-RNA bases confer a 
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C3'endo/north conformation, similar to that seen with LNAs, though there is a restriction in the 
pseudo-rotation due to the locking bridge in the LNA structure. However, studies whereby nucleotides 
have been replaced with LNAs have shown a complete loss of binding affinity, depending on the 
positioning of the LNA within the aptamer [31].  
Table 2. Incorporation of locked nucleic acids (LNA) can improve serum stability [41]. 
Modification Half-Life 
2 × LNA 2.5 fold 
3 × LNA 11 fold 
8 × LNA 15 fold 
This study replaced consecutive bases with LNAs and thus may have produced a distinctly different 
conformational shape from the original aptamer. Recent studies suggest that replacing every third 
nucleotide with LNAs would yield a near-canonical A-form heteroduplex, similar to natural RNA 
strands [41]. Again, any modification of the aptamer, especially in the binding region could lead to a 
complete loss of binding capacity as seen with the thrombin binding DNA aptamer. A single LNA was 
inserted into the aptamer at the 3'-end of the sequence resulting in a decreased binding affinity. Other 
attempts to modify this aptamer failed to improve binding affinity though 3'-capping of a different 
thrombin aptamer with an LNA had little effect on binding [41]. These results suggest that while it 
may be possible to predict to some extent the effect that modifications may have on binding affinity, it 
is still a trial and error process, especially in the case of substituting DNA nucleotides for LNAs. 
However, if there is a distinct binding region in the aptamer structure, such as that seen with the Sgc8 
T cell leukaemia aptamer or the TD05.17 membrane bound IgM B cell receptor aptamer produced by 
the Tan group [32,42], it should theoretically be possible to modify the DNA aptamers in the  
non-binding stem region of the aptamer without a loss in binding affinity [41,43] (Figure 3). However, 
as Figure 3 shows, replacing purines or pyrimidines in the stem region with LNAs may affect the 
binding affinity or the aptamer. In this case it appears that the substitution of LNAs in the 5'-end of the 
aptamer (Figure 3B,D) had a detrimental effect on binding affinity, probably due to conformational 
changes which affected the binding region. However, substitutions in the 3'-end of the aptamer slightly 
increased binding affinity (Figure 3C). This study shows that even the stem region can be involved in 
binding to the target. 
In comparison with LNAs, the unlocked nucleic acid (UNA) is an acyclic ribose derivative that has 
increased flexibility. UNAs lack the C2'-C3' bond which confers the flexibility observed in this 
modified nucleotide [44] (Figure 2A). Whereas LNAs can increase the melting temperature of the 
nucleotide by 1 °C–10 °C per LNA insertion, UNAs will typically reduce the melting temperature by 
up to 5 °C–10 °C, though they still retain their resistance to nucleases [41,44]. As with LNAs, 
depending on the positioning of the UNA into the aptamer structure, these UNAs can either decrease 
or increase the specificity of target binding. UNAs are much easier to synthesise and produce higher 
yields than LNAs [45]. Interestingly, while LNA modification of the thrombin binding aptamer 
resulted in lower binding affinity, the insertion of UNAs into the sequence actually increased the 
binding affinity [41,44].  
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Figure 3. The insertion of modified bases into the structure of an aptamer can have 
profound effects on binding affinity. The DNA aptamer TD.05 was modified with locked 
nucleic acids in the stem region. (A) unmodified DNA aptamer; (B) the last four bases of 
the aptamer in the stem region were replaced with locked nucleic acids; (C) only the last 
four bases on the 3'-end of the aptamer were replaced with locked nucleic acids; (D) the 
first four bases on the 5'-end were modified with locked nucleic acids. Red boxes indicated 
substituted bases. Modified from [43]. 
 
3. Modified-SELEX and the Incorporation of Serum-Stable Nucleotides 
Post-SELEX modification can adversely affect the binding affinity and abolish specificity in target 
interaction. This has had a limiting effect on the use of aptamers as therapeutic agents. Therefore, 
being able to incorporate modified nucleic acids into the RNA transcription reaction that forms part of 
each iterative round of selection greatly increases the chance of successfully selecting RNA aptamers 
with effective serum stability. A key aspect to this has been the demonstration of using modified 
nucleotides as substrates of the transcription enzymes [46]. The discovery and production of enzymes 
that are capable of an in vitro transcription reaction incorporating modified bases into the nucleic acid 
strands has revolutionised the use of aptamers, and nucleic acids in general, as therapeutic agents. 
Seminal work by Padilla and Sousa demonstrated that the Y639F variant of T7 RNA polymerase could 
incorporate 2'-amino and 2'-fluoro-pyrimidines into the transcription reaction [47]. RNA polymerases, 
such as T7 RNA polymerase and AMV reverse transcriptase have been shown to be capable of 
incorporating modified bases during the transcription process [26,46]. To date, 2'-aminopyrimidines, 
2'-O-methylpurines, and 2'-fluoropyrimidines have been incorporated in this way [46,48,49].  
One of the reasons that RNA aptamers have been consistently used for in vivo applications is its 
ability to incorporate modified nucleotides into the selection process during the transcription reaction. 
In contrast, DNA polymerase chemistry has lagged behind the ability to use RNA polymerases such as 
T7 and SP6. There are now several commercially available thermostable DNA polymerases capable of 
inserting modified nucleotides during the PCR reaction. It has been suggested that DNA polymerases 
derived from Thermococcus kodakaraensis, such as KOD Dash, are the most efficient tools for 
incorporation of modified DNA [29]. Modifications or substitutions at the C5 position of pyrimidines 
or the C7 position of 7-dezapurines are fairly well tolerated by DNA polymerases [50]. Indeed, the 
KOD Dash polymerase has successfully been used to incorporate a modified thymidine analogue with 
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a cationic ammonium group attached via a hydrophobic hexamethylene linker at the C5 position 
during the selection process [51]. As well, a recent report has shown the incorporation of uracil bases 
modified at the C5 position with a N-(2-(N
6
-adeninyl)ethyl))carbamylvinyl group during selection. 
When compared to natural aptamers selected against the same target, the modified DNA aptamer 
showed substantially higher binding affinities (1.1 µM vs 0.039 and 0.086 µM) [50]. Of note, Vaught 
and colleagues have successfully incorporated six different C5-modified dUTP derivatives using KOD 
Dash or Deep vent polymerases during PCR and were able to generate DNA aptamers against a 
previously refractory protein, tumour necrosis factor receptor superfamily member 9 [52]. It was this 
work that led to the generation of SOMAmers, or slow off-rate modified aptamers, which can be used 
to select against any target, even previously difficult protein targets for which standard RNA and DNA 
SELEX proved to be incapable of producing high affinity binding species [53]. This is due to the fact 
that these modified nucleotides increase the structural diversity, thus broadening the range of 
accessible protein targets [54]. 
Interestingly, KOD, Phusion High Fidelity DNA polymerase, Superscript III and the T7 polymerase 
have all been shown to be capable of incorporating LNA triphosphates into DNA and RNA  
strands [41,45,55,56], which opens up a new era in aptamer selection strategies. However, lower 
coupling efficiencies may preclude classical SELEX which involves 8–12 iterative rounds. Indeed, a 
recent study using a DNA random library and High Fusion DNA polymerase and KOD XL DNA 
polymerase successfully incorporated LNA-ATP into the DNA strand of 40 nucleotides. However, the 
level of LNA ATP incorporation dropped from 20.5% in round one to 6.6% in round 7. This decrease 
was more pronounced when using LNA-TTP, with a drop from 31% at round one to 6.8% at  
round 3 [57]. Using capillary electrophoresis SELEX, LNA aptamers were selected against thrombin 
using a mix of KOD polymerases, though there was no discussion of incorporation efficiency [58]. 
The authors did note, however, that selection was not simple [59]. Further work by this group used 
LNAs in the primer region of the randomised library for selection, a strategy that proved successful for 
the in vitro selection of LNA aptamers [59,60]. While these results have shown that it is possible to 
insert LNAs into the DNA aptamers during the selection process, additional modifications have been 
required to improve the reaction efficiency before DNA aptamers can compete with their RNA 
counterparts in traditional SELEX selection. Pinheiro and colleagues developed new Tgo DNA 
polymerase variants which were capable of incorporating xeno-nucleic acids during transcription  
and reverse transcription [61]. 
4. Functionalisation as A Means of Producing Effective Diagnostic Tools 
A recent article in this journal has reviewed the use of aptamers as efficient tools in numerous 
analytical applications [62]. These analytical applications do not necessarily require a serum stable 
aptamer though they would certainly be advantageous. Diagnostic applications requiring high serum 
stability are those with future in vivo applications. The ability to attach any reporter molecule to the 
aptamer structure has far reaching implications in the field of cancer medicine. The ability to detect 
small cancer foci and monitor disease response to treatment has the potential to guide and influence 
clinicians decision-making with regard to therapeutic choices. Additionally, if these molecules could 
both act as imaging agents and therapeutic tools at the same time, there would be long-term benefits to 
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the patient. Dyes, such as Cy5 [63], have been superseded by the advent of quantum dots. There have 
been a number of papers published over the last decade describing the use of quantum dots (QDs) as 
novel in vivo imaging agents [64–67]. QDs are small novel fluorophores that have distinct emission 
profiles based on their sizes. One single QD can have multiple copies of the same aptamer or different 
aptamers bound to their surface [68,69]. Each aptamer can also be base-paired to a complimentary 
strand that carries a quencher, with this strand being displaced upon binding to its target, thus resulting 
in a large increase in fluorescence emission [70]. However, other quenchers can also be used for  
in vivo applications, of which doxorubicin (Dox) is very promising in cancer medicine. Dox is a 
commonly used frontline anthracycline chemotherapeutic drug that intercalates into double-stranded 
GC sequences of DNA and RNA. The use of Dox is limited in dosage due to cardiotoxicity. Through 
the use of targeted therapeutics, the dose of the drug can be reduced, thus allowing either a  
more prolonged exposure of the drug to cancer cells and/or repeated dosing. Dox has known 
fluorescent properties which are rapidly quenched upon intercalation into DNA [71,72]. Through a  
Bi-Fluorescence Resonance Energy Transfer (FRET) mechanism, the QDs and Dox act as  
donor-acceptor, where the fluorescence of the QDs is quenched by the Dox absorbance, and the Dox 
fluorescence is quenched by the aptamer in a donor-quencher manner. When this 2'-fluoropyrimidine 
modified aptamer-Dox-QD is delivered in vivo no fluorescent signal is observed. However, once the 
aptamer has specifically internalised into the cell, there is a gradual release of Dox from the aptamer 
which then “switches on” the fluorescence of the QD, thus allowing visualisation of the cancer  
cells [73]. This same aptamer has also been thermally cross-linked to superparamagnetic iron oxide 
nanoparticles (TCL-SPION), which can be used as magnetic resonance imaging (MRI) contrast agents. 
With the addition of Dox to the aptamer stem, this nanoparticle has been shown to effectively target 
prostate cancer cells [74]. Thus, this study indicates the potential of aptamers to act as theranostic 
agents. Indeed, as simple as Dox is to intercalate into the stem of aptamers, so it is a relatively 
straightforward procedure to link siRNA to the end of aptamers [75]. As well, simple fluorophores can 
be attached to the end of the aptamer and the siRNA sequence, thus allowing real time in vivo 
localisation studies. This is an important consideration with siRNA delivery to ensure that the siRNA 
remains linked to the aptamer until specific delivery to the correct cell.  
5. Conclusions 
With the advances in nucleic acid chemistry and technological applications, it is now possible to use 
aptamers in almost every application that antibodies have been successfully used for to date. Unlike 
antibodies that may lose their specificity or sensitivity through functionalisation, aptamers generally do 
not. As well, as aptamers are far smaller in size than antibodies and even antibody fragments, the 
addition of drugs or fluorescent molecules will not severely impact on their ability to penetrate deeply 
into organs or tumours. With the ability of modifying these nucleic acids through the selection process, 
and using rational design to modify them post-SELEX, aptamers have the ability to be used 
successfully in vivo. The ability to engineer these aptamers to be nuclease resistance through simple 
nucleotide swaps and functionalisation will revolutionise the medical field. With one aptamer already 
approved by the FDA, and numerous more in clinical trials, it will only be a short time before these 
novel small molecules enter the mainstream pharmaceutical pipelines. 
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